TNFRSF9 and cancer: CAR comprises an extracellular, cancer-specific antibody fused with the intracellular signaling activation domains of CD3 and co-activation ligands, such as CD28 or 4-1BB [17, 18], which provide engineered T cells with an MHC‐independent mechanism through which to kill cancer cells directly.